Wuhan Jianmin Pharmaceutical Group Co., Ltd. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Wuhan Jianmin Pharmaceutical Group Co., Ltd. with three other
companies in this sector in China:
Chengdu Kanghong Pharmaceutical Group Co Ltd
sales of 2.74 billion Chinese Renmimbi [US$433.54 million]
SSY Group Ltd
(2.66 billion Chinese Renmimbi [US$420.77 million]
of which 96%
was Intravenous Infusion Solution and Others), and
Sihuan Pharmaceutical Holdings Group Ltd
(2.75 billion Chinese Renmimbi [US$434.66 million]
Wuhan Jianmin Pharmaceutical Group Co., Ltd. reported sales of 2.71 billion Chinese Renmimbi (US$429.23 million)
December of 2017.
increase of 14.7%
versus 2016, when the company's sales were 2.36 billion Chinese Renmimbi.
This was the third consecutive year of growth at Wuhan Jianmin Pharmaceutical Group Co., Ltd..
Sales of Pharmaceutical saw an increase
23.5% in 2017, from
855.80 million Chinese Renmimbi to 1.06 billion Chinese Renmimbi.